Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?

British Journal of Cancer

Volumn 113, Issue 3, 2015, Pages 403-410

  Zanders, M M J ^a   Van Herk Sukel, M P P ^b   Vissers, P A J ^a,c   Herings, R M C ^b   Haak, H R ^d,e,f   Van De Poll Franse, L V ^a,c  

^a Netherlands Comprehensive Cancer Organisation ^*  (Netherlands)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

^d Department of Internal Medicine   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; DIABETES MELLITUS; DRUG EXPOSURE; DRUG USE; EXPOSURE VARIABLE; FEMALE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSITIVITY ANALYSIS; COLORECTAL NEOPLASMS; COMPLICATION; DIABETES COMPLICATIONS; MIDDLE AGED; MORTALITY; REGISTER; RISK FACTOR; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; COLORECTAL NEOPLASMS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84938418560     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.259     Document Type: Article

References (36)

1. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR (1999) Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5(8): 2223-2229.
2. Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59(11): 1572-1585.
3. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, van den Broek CB, Coebergh JW, Herings RM, van de Velde CJ, Fodde R, Liefers GJ (2012) Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 106(9): 1564-1570.
4. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, Grassi G (2012) Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab 14(1): 23-29.
5. Cardwell CR, Hicks BM, Hughes C, Murray LJ (2014) Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol 32(28): 3177-3183.
6. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356(21): 2131-2142.
7. Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302(6): 649-658.
8. Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, Reed C, Donnan PT, Guthrie B, Leese GP, McKnight J, Pearson DW, Pearson E, Petrie JR, Philip S, Sattar N, Sullivan FM, McKeigue P (2012) Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55(11): 2929-2937.
9. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MM (2012) Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 106(8): 1374-1378.
10. Glynn RJ, Knight EL, Levin R, Avorn J (2001) Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 12(6): 682-689.
11. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343(6257): 425-430.
12. Katz MS, Minsky BD, Saltz LB, Riedel E, Chessin DB, Guillem JG (2005) Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 62(5): 1363-1370.
13. Kirkwood BR, Sterne JAC (2003) Essential Medical Statistics. Second edn Blackwell Publishing: Boston, MA, USA.
14. Kodach LL, Jacobs RJ, Voorneveld PW, Wildenberg ME, Verspaget HW, van Wezel T, Morreau H, Hommes DW, Peppelenbosch MP, van den Brink GR, Hardwick JC (2011) Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 60(11): 1544-1553.
15. Lakha F, Theodoratou E, Farrington SM, Tenesa A, Cetnarskyj R, Din FV, Porteous ME, Dunlop MG, Campbell H (2012) Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer 12: 487.
16. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH (2011) The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 131(3): 752-759.
17. Mace AG, Gantt GA, Skacel M, Pai R, Hammel JP, Kalady MF (2013) Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum 56(11): 1217-1227.
18. McCowan C, Munro AJ, Donnan PT, Steele RJ (2013) Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 49(5): 1049-1057.
19. National Cancer Institute (2014) A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer, NCT01101438. Available at http://www.clinicaltrials.gov (accessed 10 November 2014).
20. National Cancer Institute (2014) A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer, NCT01310231. Available at http://www.clinicaltrials.gov (accessed 10 November 2014).
21. Pollak M (2012a) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev 12(3): 159-169.
22. Pollak MN (2012b) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2(9): 778-790.
23. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H (2012) Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55(6): 1619-1632.
24. Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S (2013) The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev 22(10): 1877-1883.
25. Spillane S, Bennett K, Sharp L, Barron TI (2013) A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer Epidemiol Biomarkers Prev 22(8): 1364-1373.
26. Stavrou EP, Buckley N, Olivier J, Pearson SA (2012) Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open 2(3): e000880.
27. Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35(12): 2665-2673.
28. Suissa S, Azoulay L (2014) Metformin and cancer: mounting evidence against an association. Diabetes Care 37(7): 1786-1788.
29. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339(19): 1349-1357.
30. van Dijk L, Wolters I, de Bakker DH (2011) NIVEL: Farmaceutische zorg in de integrale bekostiging. Available at http://www.nivel.nl/sites/default/files/bestanden/Rapport-Farmaceutische-zorg-integrale-bekostiging.pdf (accessed on 12 March 2014).
31. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, Vreugdenhil G, Pruijt JF, Coebergh JW, Herings RM (2010) New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 46(2): 395-404.
32. Walker JJ, Johnson JA, Wild SH (2013) Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. Lancet Diabetes Endocrinol 1(2): 132-139.
33. Wang SV, Gagne JJ, Glynn RJ, Schneeweiss S (2013) Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology 24(3): 375-378.
34. World Health Organization (2014) Collaborating Centre for Drug Statistics Methodology-ATC/DDD index. Available at www.whocc.no/atc-ddd-index. (accessed 15 August 2014).
35. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, Azoulay L (2014) Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32(1): 5-11.
36. Zanders MM, Vissers PA, van de Poll-Franse LV (2014) Association between metformin use and mortality in patients with prostate cancer: explained by confounding by indication? J Clin Oncol 32(7): 701.